Clinical Trial
Published on 15 Nov 2024
Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers
in Drug Metabolism and Transport
- 2,861 views
![Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers](https://www.frontiersin.org/files/myhome article library/1478234/1478234_Thumb_400.jpg)











